Fig. 7. CIVO performance in canine lymphoma tumors demonstrates spatially restricted responses linked to drug mechanism. CIVO performance in canine lymphoma.

Slides:

Advertisements

Similar presentations

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Advertisements

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Immunologic responses after the MN-mediated cancer immunotherapy.

Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

Visual explanation of the interaction terms.

Fig. 3 CSF1 is expressed in human melanoma.

Visual explanation of the interaction terms.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 7 Correlation of NHP and human ISGs.

Biocompatibility evaluation in vivo with a mouse subcutaneous implant

Consolidated Standards of Reporting Trials flow diagram of VRC trial

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 3. Comparison of prediction performance.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Fig. 4 Deorphanization of quinine and mefloquine protein targets.

Fig. 5 Cell-free membrane cyclase assay confirms that candidate compounds are specific antagonists of hNPR1. Cell-free membrane cyclase assay confirms.

Optimization of a MYC degradation screen.

Fig. 2. Bacterial/viral score in COCONUT-conormalized whole-blood validation data sets. Bacterial/viral score in COCONUT-conormalized whole-blood validation.

Fig. 5. Col IV–Ac2-26 NPs decrease lesion area, necrotic area, and oxidative stress in brachiocephalic arterial plaques. Col IV–Ac2-26 NPs decrease lesion.

Colonization in tumor models and different modes of administration

Fig. 5. Vitamin B12 supplementation in the host altered the transcriptome of P. acnes in the skin microbiota. Vitamin B12 supplementation in the host altered.

CD mediates metabolism and efflux of crystal-derived cholesterol

Fig. 1 The structure of the 3DGraphene foam.

Fig. 3 BMS blocks functional responses in primary immune cells driven by IL-23 and IL-12. BMS blocks functional responses in primary immune.

Fig. 4 In vivo clinical trials.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 2 Activation of LRRK2 kinase in nigrostriatal dopamine neurons in human iPD postmortem brain tissue. Activation of LRRK2 kinase in nigrostriatal dopamine.

The microchip-based drug delivery device and overview of study design

Fig. 2 Spatial distribution of earthquake density derived from a catalog spanning 93 nights of the LB Array data set. Spatial distribution of earthquake.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Sensitivity analysis of cellular responses to perturbation of the DNA damage response signaling in the presence of chemotherapies. Sensitivity analysis.

Fig. 6. Prolonged miR overexpression in the adult heart reduces fibrotic scar size but compromises cardiac function after MI. Prolonged miR

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific.

Fig. 1 Microstructure of bulk UFG/nanocrystalline Cu-containing distributed WC nanoparticles. Microstructure of bulk UFG/nanocrystalline Cu-containing.

Single-cell analyses to tailor treatments

Fig. 1. CCR5-TALEN and CCR5-megaTAL activity in T cells and comparison of NHEJ and HDR events in a TLR reporter line. CCR5-TALEN and CCR5-megaTAL activity.

LTB4 production is elevated in preclinical and clinical lymphedema

Fig. 2. An automated cell phone–based video microscope.

Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs on tumor cells. Binding and antiproliferative effects of ANG4043 and anti-HER2 mAbs.

Candesartan diminishes SynO-mediated morphofunctional responses in microglia. Candesartan diminishes SynO-mediated morphofunctional responses in microglia.

Fig. 6. Confocal image series at 10-μm intervals through the full retinal thickness at P48 in WT and vldlr-null mice. Confocal image series at 10-μm intervals.

Fig. 4. HERV-K env expression and injury to lower motor neurons.

Delineating cancer evolution with single-cell sequencing

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 4 In situ extraction of cancer-related miRNAs using the nanowire-anchored microfluidic device; heat maps of the miRNA expression array for noncancer.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Multiplexed four- and eight-channel devices for rapid processing

Fig. 3 Characterization of SGN responses to optogenetic stimulation.

Fig. 2 Comparison of the observed DRs and the estimates by the VR model and FL. Comparison of the observed DRs and the estimates by the VR model and FL.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Fig. 7 BEL immune response.

Fig. 5 Clustering of the distal gut microbiome, the C

Fig. 5 Distributions of cell nuclear area values and internuclear distances in the breast tumor specimens (Figs. 3 and 4), where bin interval = 8 and n.

Fig. 5 Density plots showing the relationship between growth responses to extreme events and site-level mean precipitation from all sites (N = 1314). Density.

Fig. 3. Association between peak CTL019 expansion and response.

Fig. 3. Col IV–Ac2-26 NPs suppress lesional superoxide and increase lesional Il10 mRNA in Ldlr−/− mice with established atherosclerosis. Col IV–Ac2-26.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Fig. 2 Spatial distribution of five city groups.

Fig. 3 Postnatal assembly of the humanized gut microbiota.

Fig. 4 Rotavirus induces the type I IFN pathway and release of ATP by tumor cells. Rotavirus induces the type I IFN pathway and release of ATP by tumor.

Fig. 1. Maps of Lesotho, a landlocked country within South Africa.

Fig. 3 Spatial distribution of the shoot density (high densities are represented in dark green and low ones in bright yellow) in a simulation of a P. oceanica.

Fig. 2. Ex vivo and in vivo investigation of the mechanism of drug delivery enhancement with ultrasound. Ex vivo and in vivo investigation of the mechanism.

Presentation transcript:

Fig. 7. CIVO performance in canine lymphoma tumors demonstrates spatially restricted responses linked to drug mechanism. CIVO performance in canine lymphoma tumors demonstrates spatially restricted responses linked to drug mechanism. (A to C) CIVO microinjection procedure adapted for a clinic-like, veterinary setting (A and B) by incorporating the placement of a “guide needle” into the optimal injection site using ultrasound guidance, (C) which aligned the microinjection device to target all needles of the handheld device into the optimal location in the tumor, increasing injection success. (D) ITD signal seen beneath the skin with a blue flashlight and yellow filter glasses, from a canine tumor injected using an eight-needle CIVO array. (E) Cancerous lymph nodes in two dogs were microinjected with the same amount of vincristine (1.5 μg) or a vehicle control. Tumors were resected 24 hours after microinjection. The ITD (green) and tumor responses (CC3, red; pHH3, yellow) were visualized in 4-μm sections from multiple depths along the injection column. Individual injection sites are shown for each dog. The fraction of biomarker-positive cells for each dog was plotted as a function of radial distance from the injection site. Data are average responses across three sections at about 2-mm intervals along the injection column ± SEM. Richard A. Klinghoffer et al., Sci Transl Med 2015;7:284ra58 Copyright © 2015, American Association for the Advancement of Science